ENDPOINTS NEWS7m
Telix buys ra­dio­phar­ma­cy net­work for $230M up front to ex­pand US ca­pac­i­ty
Australian radiopharma company Telix Pharmaceuticals is acquiring radioisotope manufacturer RLS Radiopharmacies in another ...
ENDPOINTS NEWS2h
Ideaya out­lines reg­u­la­to­ry path for rare eye can­cer drug af­ter pos­i­tive mid-stage da­ta
Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after ...
ENDPOINTS NEWS2h
As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
ENDPOINTS NEWS6h
UK vac­cine start­up Vice­bio snags $100M to take on GSK, Pfiz­er and Mod­er­na
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...
ENDPOINTS NEWS3h
PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships
As an­ti­body–drug con­ju­gates (AD­Cs) and im­mune check­point in­hibitors con­tin­ue to grab a lot of at­ten­tion as trans­for­ma­tive can­cer ther­a­pies, they would ap­pear to leave lit­tle room ...